Indications

China Ibrutinib Market Report 2021: By 2020, Pharmacyclics Inc is the Only Manufacturer in the Chinese Market – Forecast to 2025 – ResearchAndMarkets.com | Business

DUBLIN – (BUSINESS WIRE) – May 20, 2021 – the “Chinese Ibrutinib Market Investigation Report 2021-2025” the report was added to ResearchAndMarkets.comoffer. As of 2020, Pharmacyclics Inc is the only manufacturer in the Chinese market of ibrutinib. Ibrutinib is a BTK inhibitor, primarily used to treat B cell carcinomas, such …

Read More »